Terguride
Top View
- Terguride As a New Anti-Hyperprolactinemic Agent: Characterization in Rats and Dogs in Comparison with Bromocriptine
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- Poster 2 Xocpharma Final
- Terguride Stimulates Locomotor Activity at 2 Months but Not 10 Months After L-Methyl-4-Phenyl-L,2,3,6-Tetrahydropyridine Treatment of Common Marmosets
- Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Non-Lipid Benzofuran Ethanolamine Structures
- Coalescing Beneficial Host and Deleterious Antiparasitic Actions As an Antischistosomal Strategy John D Chan1, Timothy a Day1, Jonathan S Marchant2*
- Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures S
- Pergolide, Terguride and N,N'-Spacer-Linked Oligomers Of
- Terguride but Not Bromocriptine Alleviated Glucose Tolerance Abnormalities and Hyperlipidaemia in Obese and Lean Genetically Hypertensive Koletsky Rats
- Wo 2007/044693 A2
- 210311 Wild Guided Report.Indd
- Salvage of Sildenafil Failures with Cabergoline: a Randomized, Double-Blind, Placebo-Controlled Study
- 3527347852 Bindex.Pdf
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor
- TEVA PHARMACEUTICAL INDUSTRIES LTD. and Its Affiliates
- Evaluation of Agonist Pharmacotherapy for Cocaine Dependence: Effects of Continuous D-Amphetamine Treatment on Cocaine Self-Administration in Rats
- Early Manifestation of Communicating Hydrocephalus After Fractionated Stereotactic Radiotherapy for Aggressive Giant Atypical Prolactinoma